$MYGN News

Last published 1w ago

1w agoMYGNMYRIAD GENETICS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoMYGNMyriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth InitiativesGlobeNewswireHighlights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued progress on payer
1w agoMYGNMYRIAD GENETICS THIRD QUARTER 2026 FINANCIAL EARNINGS - MYRIAD GENETICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Myriad Genetics third quarter 2026 financial earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, th
1w agoMYGNMyriad Genetics to Participate in Upcoming Investor Healthcare ConferencesGlobeNewswireSALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will participate in three
2w agoMYGNMyriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic CancersGlobeNewswireSALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing MONSTAR-SCREEN-3 study
3w agoMYGN LHMyriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to LabcorpGlobeNewswireSALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE:LH), a global leader in
3w agoMYGNMyriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswireSALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at
1mo agoSOPH MYGN AZNSOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyPR NewswireBOSTON, Oct. 8, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ:MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to
1mo agoMYGNMyriad Genetics Appoints Vishal Sikri Executive Vice President - CommercialGlobeNewswireSALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to
2mo agoMYGNWells Fargo 21st Annual Healthcare Conference - MYRIAD GENETICS INCEarnings Call TranscriptsThank you, everyone. Welcome to the third day of the Wells Fargo Health Care Conference. I apologize, I'm losing my voice, getting a little sick, so bear with me. But this is the end of the Life Science Tools and Diagnos
2mo agoMYGNMyriad Genetics to Present at 2026 Wells Fargo Healthcare ConferenceGlobeNewswireSALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual
3mo agoMYGNMyriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and ScalabilityGlobeNewswireHighlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and
3mo agoMYGNMyriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026GlobeNewswireSALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at
3mo agoMYGNMyriad Genetics Launches FirstGene® Multiple Prenatal ScreenGlobeNewswireSALT LAKE CITY, July 21, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the full commercial launch of FirstGene® Multiple
4mo agoMYGNNew Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate CancerGlobeNewswireSALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest
4mo agoMYGNMyriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New PublicationGlobeNewswireSALT LAKE CITY, June 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™,
5mo agoMYGNMyriad Genetics Names Raj Jampa as New Chief Technology OfficerGlobeNewswireSALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa as chief technology
5mo agoMYGNMyriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual MeetingGlobeNewswireSALT LAKE CITY, May 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announces it will share data demonstrating the utility of Myriad's
5mo agoMYGNMyriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)GlobeNewswireSALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this
6mo agoMYGNActress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her LifeGlobeNewswireSALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress Jackie Tohn to raise
6mo agoMYGNMyriad Genetics to Participate in Upcoming Investor Healthcare ConferencesGlobeNewswireSALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming
6mo agoMYGNMyriad Genetics First Quarter 2026 Financial EarningsMYRIAD GENETICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Myriad Genetics first quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a questio
6mo agoMYGNMyriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum BusinessGlobeNewswireHighlights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test.First quarter 2026 test volume reflects 13% and 7%
6mo agoMYGNMyriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care PlanGlobeNewswireSALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- The latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision
6mo agoMYGNMyriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026GlobeNewswireSALT LAKE CITY, April 28, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2026 earnings conference call at
6mo agoMYGNMyriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026GlobeNewswireSALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, including two podium
7mo agoMYGNMyriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in JapanGlobeNewswireSALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Health, Labour and
7mo agoMYGNMyriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual MeetingGlobeNewswireSALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at the Society of
8mo agoMYGNMyriad Commercially Launches Precise MRD with Select Community OncologistsGlobeNewswireSALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the Precise MRD™ (molecular
8mo agoMYGNSix presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad's Precise MRD, Prolaris, and MyRisk testsGlobeNewswireSALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting
8mo agoMYGN STIM TFX ZOMDiality Appoints Peter Donato as Chief Financial OfficerBusiness WireLife sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today
8mo agoMYGNMyriad Genetics Fourth Quarter 2025 Financial EarningsMYRIAD GENETICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Myriad Genetics fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there wi
8mo agoMYGNMyriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened ExecutionGlobeNewswireHighlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025
8mo agoMYGNFirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the TestGlobeNewswireSALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical validation of the
8mo agoMYGNMyriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026GlobeNewswireSALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at
9mo agoMYGNMyriad Advances MRD Commercialization Timeline, Bolstered by New Study DataGlobeNewswireSALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise
10mo agoMYGNMyriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial GuidanceGlobeNewswireSALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the
10mo agoMYGNMyriad Genetics to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at
11mo agoMYGNMyriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer SymposiumGlobeNewswireSALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the 2025
11mo agoMYGNClairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast HealthGlobeNewswireBOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ:MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high
1y agoMYGNMyriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical NeedsGlobeNewswireSALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk® Hereditary Cancer Test—the gold
1y agoMYGNMyriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual ConferenceGlobeNewswireSALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting
1y agoMYGN SOPHMyriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid ExecutionGlobeNewswireHighlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter
1y agoMYGNNew Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better SoonerGlobeNewswireSALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in
1y agoMYGNMyriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025GlobeNewswireSALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30
1y agoMYGNMyriad Genetics Adds F8, FXN Genes to Foresight Universal Plus PanelGlobeNewswireSALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has added two genes, F8 and FXN, to the
1y agoMYGNBreast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTVGlobeNewswireData Shows Misconceptions Fuel Cancer Fears but Genetic Testing Can Help New Myriad Genetics Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by
1y agoMYGN SOPHMyriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid BiopsyPR NewswireMyriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology ...
1y agoMYGN SOPHMyriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid BiopsyGlobeNewswireSALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (NASDAQ:SOPH), an AI technology company
1y agoMYGNMyriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts